Entera Bio (STU:5DT) E10: €-0.73 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5DT Entera Bio Ltd STU:5DT
33 GF Score
Price €1.41
! 2 Warning Signs
View Full Analysis

What is Entera Bio E10?

Entera Bio STU:5DT -2.08% 33 E10 is €-0.73 as of Mar. 2026. GuruFocus rates STU:5DT with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Entera Bio's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.061. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.73 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-14), Entera Bio's current stock price is €1.41. Entera Bio's E10 for the quarter that ended in Mar. 2026 was €-0.73. Entera Bio's Shiller PE Ratio of today is .


Entera Bio  (STU:5DT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Entera Bio E10 Related Terms


Entera Bio E10 Historical Data

* Premium members only.

The historical data trend for Entera Bio's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entera Bio E10 Chart

Entera Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entera Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.73

STU:5DT vs HRTX, OKYO, EDSA: E10 Comparison

For the Biotechnology subindustry, Entera Bio's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entera Bio Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Entera Bio's Shiller PE Ratio falls into.


STU:5DT
33GF Score
Entera Bio Ltd STU:5DT
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entera Bio E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Entera Bio's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.061/330.2130*330.2130
=-0.061

Current CPI (Mar. 2026) = 330.2130.

Entera Bio Quarterly Data

per share eps CPI Adj_EPS
201512 0.000 236.525 0.000
201606 -0.211 241.018 -0.289
201609 -0.181 241.428 -0.248
201612 -0.530 241.432 -0.725
201706 -0.348 244.955 -0.469
201709 -0.437 246.819 -0.585
201712 -0.372 246.524 -0.498
201803 -0.295 249.554 -0.390
201806 -0.094 251.989 -0.123
201809 -0.386 252.439 -0.505
201812 -0.149 251.233 -0.196
201903 -0.230 254.202 -0.299
201906 -0.106 256.143 -0.137
201909 -0.227 256.759 -0.292
201912 -0.234 256.974 -0.301
202003 -0.145 258.115 -0.186
202006 -0.151 257.797 -0.193
202009 -0.076 260.280 -0.096
202012 -0.205 260.474 -0.260
202103 -0.084 264.877 -0.105
202106 -0.083 271.696 -0.101
202109 -0.094 274.310 -0.113
202112 -0.133 278.802 -0.158
202203 -0.118 287.504 -0.136
202206 -0.104 296.311 -0.116
202209 -0.111 296.808 -0.123
202212 -0.094 296.797 -0.105
202303 -0.075 301.836 -0.082
202306 -0.074 305.109 -0.080
202309 -0.075 307.789 -0.080
202312 -0.064 306.746 -0.069
202403 -0.046 312.332 -0.049
202406 -0.056 314.175 -0.059
202409 -0.072 315.301 -0.075
202412 -0.057 315.605 -0.060
202503 -0.055 319.799 -0.057
202506 -0.052 322.561 -0.053
202509 -0.060 324.800 -0.061
202512 -0.060 324.054 -0.061
202603 -0.061 330.213 -0.061

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.73 mean?
Entera Bio (STU:5DT) has a E10 of €-0.73 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Entera Bio and its competitors.
Is Entera Bio's E10 too high?
Entera Bio's current E10 is €-0.73. Overall, Entera Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's E10 compare to HRTX and OKYO?
Entera Bio's E10 of €-0.73 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Entera Bio and its competitors. Entera Bio's current E10 is €-0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (STU:5DT) has a current E10 of €-0.73. The current E10 is €-0.73. Entera Bio's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Entera Bio (STU:5DT), the current E10 is €-0.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entera Bio Business Description

Other Exchanges ENTX:USA
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
33GF Score

Get the complete analysis for STU:5DT

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.41
Price